Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis

Seven patients with pustular psoriasis, three with mutations in IL36RN , were treated with a monoclonal antibody against interleukin-36 receptor and had amelioration of their skin disease.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2019-03, Vol.380 (10), p.981-983
Hauptverfasser:	Bachelez, Hervé, Choon, Siew-Eng, Marrakchi, Slaheddine, Burden, A. David, Tsai, Tsen-Fang, Morita, Akimichi, Turki, Hamida, Hall, David B, Shear, Michael, Baum, Patrick, Padula, Steven J, Thoma, Christian
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Intravenous Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - immunology Antibodies, Monoclonal, Humanized - therapeutic use Cytokines Drug dosages Female Humans Interleukins - genetics Interleukins - metabolism Male Monoclonal antibodies Mutation Psoriasis Psoriasis - drug therapy Receptors, Interleukin - antagonists & inhibitors Severity of Illness Index Skin diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Seven patients with pustular psoriasis, three with mutations in IL36RN , were treated with a monoclonal antibody against interleukin-36 receptor and had amelioration of their skin disease.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMc1811317